One ratio decides the stock — and it sits in dispute

• The whole case is the medical care ratio. On a ~1% net margin, a 260 basis-point jump in the consolidated MCR to 91.7% in 2025 vaporized ~60% of net income; on management's own math each point is worth roughly $6 of EPS. Every other line resolves once the ratio steps down — or doesn't.
• Cyclical, says the bull. CMS requires Medicaid rates to be 'actuarially sound,' so states must restore rate to the higher cost baseline on a lag; the first post-trough quarter already bent favorable, with the consolidated MCR easing to 91.1% and cost trend 'modestly favorable' to plan.
• Structural, says the bear. Management itself concedes Medicaid 'needs 300 to 500 basis points to break even, just to break even,' and one tentative quarter with Medicaid still near 92% is not a trend.

A record-revenue year that still cut earnings in half

On every premium dollar, ~92 cents now goes to medical claims and ~6.6 cents to overhead, leaving pennies of profit — so a sector-wide cost spike plus a redetermination-driven acuity shift was enough to halve earnings. Cash flow swung negative largely on the timing of government settlements, not just lower profit. Worth pricing in: a reserve cushion that lifted 2022–2024 margins — favorable prior-year development reached $675M in 2024 — collapsed to $98M in 2025.

The low-cost moat passed its worst stress test

• Profitable while its twin lost $6.7B. In the worst managed-care cost year in a decade, Molina held a positive margin while Centene — the only other pure government-program operator — posted a $6.7 billion net loss; management reads its Medicaid pre-tax margin as 'industry-leading by 300 to 400 basis points.'
• The contract engine kept winning. A 90% renewal and 80% new-contract RFP win rate added nearly $9 billion of new 2025 premium, headlined by the sole-source Florida Children's Medical Services award (~$6 billion run-rate, term through 2030).
• Over $11 a share of profit already contracted. 'Embedded earnings' — future profit from won-but-immature contracts — climbed past $11 per share by year-end 2025, rising every quarter as reported EPS collapsed.

The stock has already paid for the recovery

• A near-vertical round trip. Shares bottomed at $122.65 on February 11, 2026 and re-rated ~76% to ~$216 — within a hair of the all-time high — on a single quarter of cost-trend stabilization.
• Above where the Street will go. At ~$216 the stock trades ~42x the FY2026 floor of 'at least $5' adjusted EPS and 2.8x book, yet the sell-side mean target near $192 sits below the quote — analysts on average see downside.
• A twenty-handle name now. The last four earnings prints averaged a ~19% one-day move; into the July 22 Q2 report the near-term skew is asymmetric to the downside, with the easy mean-reversion from the low already banked.

Management reset 'normal' to a permanently lower margin

• It raised its own loss-ratio target. At its May 2026 Investor Day, Molina lifted its long-term Medicaid MCR target from 88–89% to 91.5–92.5% — telling investors the old ~88% ratio, and the $20-plus EPS it produced, is not coming back.
• Volume over margin. To bridge to a $25 adjusted-EPS 2029 target on a thinner margin, it simultaneously raised the Medicaid organic-growth target from 7–9% to 12–14% — coherent for a price-taker, but it leans harder on the growth engine.
• A legislated, shrinking base. OBBBA work requirements are expected to cut 15–20% of ~1.2 million Medicaid expansion members by 2029, and on the Q1 call management raised its 2026 attrition assumption from 2% to 6%.